R&D and orphan drug tax credits
Executive Summary
Would be renewed through June 30, 1992, in a package of 12 tax credit extensions approved by Congress Nov. 26. The House Ways & Means and Senate Finance Committees adopted the measure on Nov. 25. Absent legislative action, tax credits for corporations' research and development expenditures and for orphan drug development costs would expire with the end of the calendar year. . . .